Day 1: Agenda & Speakers Slides
Day 2: Agenda & Speakers Slides
Print Agenda (PDF)

Friday, September 27

8:15 – 8:55 AM 

Registration and Continental Breakfast

8:55 – 9:00 AM 

FDLI Welcome
Steven Leslie, Assistant Director, Educational Programs, FDLI

9:00 – 10:00 AM 

Back by popular demand, this session will feature insights from in-house counsels at industry manufacturers who will share their most pressing legal issues, what keeps them up at night, and how they approach these challenges.

Lanny Schimmel, Vice President, Secretary, and General Counsel, Kerry, Inc.
Stephen L. Lacey, Division Vice President and Associate General Counsel, Nutrition, Abbott Laboratories
John Luedke, General Counsel – Global Food Law, Mars, Inc
Moderated by August T. Horvath, Partner, Foley Hoag LLP

10:00 – 10:45 AM

This panel will discuss Prop 65 developments over the past year, including the new safe harbor warnings, the potential listing of marijuana as a reproductive toxicant, and litigation over glyphosate, lead, and acrylamide.  Panelists will also discuss new and emerging issues that have arisen as food manufacturers implement the regulations, as well as New York’s proposed Consumer Right to Know Act, which has been dubbed “Prop 65 Lite.”

Tamany Vinson Bentz, Partner, DLA Piper
Trenton H. Norris, Partner, Arnold & Porter LLP

10:45 – 11:00 AM

Coffee and Networking Break

11:00 AM – 12:00 PM 

This session will look at the current state of industry class action litigation from the perspective of an outside defense attorney, plaintiff’s attorney, in-house counsel, and litigation consultant. Panelists will cover a wide range of topics, including the recent trend of challenging “natural” and other label claims based on the use of multi-function ingredients, developments and issues in dietary supplement class actions, the role of pre-suit demand letters and litigation strategy, and challenges to maintaining and settling cases, such as data aggregation.

Dale J. Giali, Partner, Mayer Brown
Kirstin Mazzeo, Chief Counsel – Litigation, Campbell Soup Company
Timothy Snail, Ph.D, Vice President, Charles River Associates
Michael R. Reese, Founding Partner, Reese LLP

12:00 – 1:15 PM

Networking Luncheon

1:00 – 2:00 PM 

While the 2018 Farm Bill declassified hemp and hemp-derived products as a Schedule I controlled substance, it expressly preserved FDA’s authority to regulate products containing cannabis or related compounds. However, this has not stopped the proliferation of CBD-containing food, beverage, and dietary supplement products from becoming available on the market, both online and in retail stores. This panel will provide an overview FDA actions regarding cannabis products, what upcoming changes may be on the horizon, and strategies for managing risks in an evolving regulatory landscape.

Marc C. Sanchez, Regulatory Counsel, CIHCC, LLC (d/b/a FDA Atty)
Stefanie Jill Fogel, Partner, DLA Piper
Sharon Mayl, Senior Advisor for Policy, FDA
Moderated by Allison Fulton, Partner, Sheppard Mullin, Richter & Hampton LLP 

2:00 – 3:00 PM 

A majority of states now allow at least limited medical use of marijuana, and several states have recently enacted laws legalizing certain CBD products.  These laws are at odds with federal prohibitions on both marijuana and CBD as an ingredient in food and dietary supplement products.  This panel will examine the ethical issues of representing medical marijuana and CBD product manufacturers in light of the tension between state and federal laws.

Lauren A. Farrugia, Associate, Saul Ewing Arnstein & Lehr LLP
Seth A. Goldberg, Partner, Duane Morris LLP
Mark Mansour, Partner, Locke Lord LLP

3:00 PM

Conference Adjournment